Abstract:Cisplatin is a commonly used chemotherapeutic agent with proven efficacy in treating various malignancies, including testicular, ovarian, cervical, breast, bladder, head and neck, and lung cancer. Cisplatin is also used to treat tumors in children, such as neuroblastoma, osteosarcoma, and hepatoblastoma. However, its clinical use is limited by severe side effects, including ototoxicity, nephrotoxicity, neurotoxicity, hepatotoxicity, gastrointestinal toxicity, and retinal toxicity. Cisplatin-induced ototoxicity manifests as irreversible, bilateral, high-frequency sensorineural hearing loss in 40–60% of adults and in up to 60% of children. Hearing loss can lead to social isolation, depression, and cognitive decline in adults, and speech and language developmental delays in children. Cisplatin causes hair cell death by forming DNA adducts, mitochondrial dysfunction, oxidative stress, and inflammation, culminating in programmed cell death by apoptosis, necroptosis, pyroptosis, or ferroptosis. Contemporary medical interventions for cisplatin ototoxicity are limited to prosthetic devices, such as hearing aids, but these have significant limitations because the cochlea remains damaged. Recently, the U.S. Food and Drug Administration (FDA) approved the first therapy, sodium thiosulfate, to prevent cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors. Other pharmacological treatments for cisplatin ototoxicity are in various stages of preclinical and clinical development. This narrative review aims to highlight the molecular mechanisms involved in cisplatin-induced ototoxicity, focusing on cochlear inflammation, and shed light on potential antioxidant and anti-inflammatory therapeutic interventions to prevent or mitigate the ototoxic effects of cisplatin. We conducted a comprehensive literature search (Google Scholar, PubMed) focusing on publications in the last five years.

Apoptosis, autophagy, ferroptosis, and pyroptosis in cisplatin-induced ototoxicity and protective agents

Cisplatin ototoxicity mechanism and antagonistic intervention strategy: a scope review

Current Strategies to Combat Cisplatin-Induced Ototoxicity

Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies

Cisplatin-induced ototoxicity: From signaling network to therapeutic targets

Autophagy-dependent ferroptosis contributes to cisplatin-induced hearing loss

Mechanisms of Cisplatin-Induced Ototoxicity and Prevention

Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection

Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions

Mechanisms of cisplatin ototoxicity: theoretical review

Cisplatin Ototoxicity Mechanisms and Prevention with Locally Delivered Antioxidant Drugs

The PERK/ATF4/CHOP signaling branch of the unfolded protein response mediates cisplatin-induced ototoxicity in hair cells

Role of autophagy in cisplatin-induced ototoxicity

Cisplatin-Induced Ototoxicity: Updates on Molecular Targets

Mechanisms of cisplatin ototoxicity and progress in otoprotection

Molecular Mechanisms of Chemoresistance and Cytotoxicity Associated with Platinum Drugs

Oxidative Stress and Inflammation Caused by Cisplatin Ototoxicity

Sirtuin 1 and Autophagy Attenuate Cisplatin-Induced Hair Cell Death in the Mouse Cochlea and Zebrafish Lateral Line

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

Supporting Cells and Their Potential Roles in Cisplatin-Induced Ototoxicity